InnoCare Pharma Limited (HKG:9969)
11.89
+0.14 (1.19%)
May 28, 2026, 9:30 AM HKT
InnoCare Pharma Employees
InnoCare Pharma had 1,176 employees as of June 30, 2025. The number of employees increased by 87 or 7.99% compared to the previous year.
Employees
1,176
Change
87
Growth
7.99%
Revenue / Employee
2.44M HKD
Profits / Employee
705.89K HKD
Market Cap
24.43B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 1,176 | 87 | 7.99% |
| Dec 31, 2023 | 1,089 | 150 | 15.97% |
| Dec 31, 2022 | 939 | 218 | 30.24% |
| Dec 31, 2021 | 721 | 269 | 59.51% |
| Dec 31, 2020 | 452 | 238 | 111.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,165 |
| Shanghai Henlius Biotech | 3,762 |
| Shanghai Junshi Biosciences | 2,903 |
| Zai Lab | 1,784 |
| Keymed Biosciences | 1,625 |
| Biocytogen Pharmaceuticals (Beijing) | 1,443 |
| Ascentage Pharma Group International | 605 |
| Duality Biotherapeutics | 231 |
InnoCare Pharma News
- 15 hours ago - InnoCare Announces Approval of Orelabrutinib in Australia - GlobeNewsWire
- 5 days ago - 2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released - GlobeNewsWire
- 14 days ago - InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor - GlobeNewsWire
- 20 days ago - InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China - GlobeNewsWire
- 20 days ago - InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China - GlobeNewsWire
- 4 weeks ago - InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE - GlobeNewsWire
- 4 weeks ago - InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability - GlobeNewsWire
- 4 weeks ago - InnoCare Pharma Quarterly report: Q1 2026 - Filings